(Q57904432)

1

object named as

M A Dimopoulos

0 references

M Spyropoulou-Vlachou

8

object named as

M Spyropoulou-Vlachou

0 references

author name string

M Roussou

2

0 references

M Gkotzamanidou

3

0 references

N Nikitas

4

0 references

E Psimenou

5

0 references

D Mparmparoussi

6

0 references

C Matsouka

7

0 references

E Terpos

Renal failure in multiple myeloma: incidence, correlations, and prognostic significance

9

0 references

publication date

5 July 2012

0 references

published in

Leukemia

0 references

volume

27

0 references

issue

2

0 references

page(s)

423-429

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Meeting the unmet needs in anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Bortezomib-induced survival signals and genes in human proximal tubular cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

Renal failure in multiple myeloma. Pathogenesis and prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

7 January 2021

Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

7 January 2021

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

7 January 2021

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

7 January 2021

Renal improvement in myeloma with bortezomib plus plasma exchange

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

7 January 2021

Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.182

7 January 2021